Get the Stockscreener App
4.59
8.20%
-0.41
After Hours:
4.58
-0.010
-0.22%
Alumis Inc stock is traded at $4.59, with a volume of 103.21K.
It is down -8.20% in the last 24 hours and down -10.00% over the past month.
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies.
See More
Previous Close:
$5.00
Open:
$5
24h Volume:
103.21K
Relative Volume:
0.55
Market Cap:
$249.73M
Revenue:
-
Net Income/Loss:
$-238.77M
P/E Ratio:
-0.1712
EPS:
-26.808
Net Cash Flow:
$-216.62M
1W Performance:
-10.00%
1M Performance:
-10.00%
6M Performance:
-60.40%
1Y Performance:
+0.00%
1-Day Range:
$4.57
$5.01
1-Week Range:
$4.534
$5.05
52-Week Range:
$4.36
$13.50
Alumis Inc Stock (ALMS) Company Profile
Name
Alumis Inc
Sector
Industry
Phone
650-231-6625
Address
280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Compare ALMS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALMS
Alumis Inc
|
4.59 | 249.73M | 0 | -238.77M | -216.62M | -26.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Alumis Inc Stock (ALMS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-25 | Initiated | Oppenheimer | Outperform |
| Oct-31-24 | Initiated | Robert W. Baird | Outperform |
| Oct-17-24 | Initiated | H.C. Wainwright | Buy |
| Jul-23-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-23-24 | Initiated | Guggenheim | Buy |
| Jul-23-24 | Initiated | Leerink Partners | Outperform |
| Jul-23-24 | Initiated | Morgan Stanley | Overweight |
View All
Alumis Inc Stock (ALMS) Latest News
Drug developers Pliant and Acelyrin adopt poison pill provisions to fend off activist investor - San Francisco Business Times
Metal-Organic Frameworks Market to Reach $949.2 Million by 2029, Growing at 15.6% CAGR - GlobeNewswire Inc.
Acelyrin Adopts Poison Pill to Ward Off Tang Capital Buy - BioSpace
ACELYRIN Adopts Limited-Duration Stockholder Rights Plan - EIN News
Alumis (NASDAQ:ALMS) Receives Buy Rating from HC Wainwright - Defense World
How a skin drug trial could help Peninsula biotech pull off key merger - The Business Journals
H.C. Wainwright maintains Alumis stock Buy rating, $19 target By Investing.com - Investing.com South Africa
Alumis to Present at Leerink's 2025 Global Healthcare Conference - StockTitan
Promising Efficacy of Alumis Inc.’s ESK-001 in Psoriasis Treatment Boosts Market Position and Buy Rating - TipRanks
Alumis announces data from the OLE of its Phase 2 STRIDE trial - TipRanks
Alumis Says Phase 3 Onward Program Ongoing With Topline Data Expected In Q1 2026 - Marketscreener.com
Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis - The Manila Times
New Psoriasis Drug Maintains Remarkable 61% Skin Clearance After One YearKey Trial Results - StockTitan
Acelyrin, Alumis reaffirm strategic, financial rationale of proposed merger - TipRanks
Acelyrin falls as Acelyrin reaffirms deal commitment - MSN
Acelyrin rebuffs Concentra bid, believing Alumis option better - The Pharma Letter
Acelyrin Rejects Concentra’s Buyout Offer in Favor of Alumis Merger - BioSpace
Promising Developments in Alumis Inc.’s Clinical Programs Support Buy Rating - TipRanks
Acelyrin To Proceed With Alumis Merger, Spurn Concentra Bid - Citeline News & Insights
Sector Update: Health Care Stocks Lower Tuesday Afternoon -March 04, 2025 at 02:01 pm EST - Marketscreener.com
Acelyrin Reaffirms Merger Deal With Alumis -March 04, 2025 at 10:13 am EST - Marketscreener.com
Acelyrin stock falls on Acelyrin deal commitment (SLRN:NASDAQ) - Seeking Alpha
Alumis Inc. Announces Merger with ACELYRIN, Inc. - TipRanks
ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger - The Manila Times
Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger - The Manila Times
Alumis Inc. and ACELYRIN, Inc. Confirm Commitment to All-Stock Merger to Create Leading Biopharma Company in Immune-Mediated Diseases - Nasdaq
Alumis And Acelyrin Reaffirm Strategic And Financial Rationale Of Proposed Merger -March 04, 2025 at 09:06 am EST - Marketscreener.com
ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not ... - Eagle-Tribune
Can This Biopharma Merger's $737M War Chest Transform Immune Disease Treatment? - StockTitan
Acelyrin stock down after reaffirming Alumis deal (SLRN:NASDAQ) - Seeking Alpha
Alumis (NASDAQ:ALMS) Given “Buy” Rating at HC Wainwright - Defense World
Promising Prospects for Alumis Inc.’s TYK2 Inhibitor A-005: Analyst Reiterates Buy Rating with $19 Price Target - TipRanks
Alumis presents new psoriasis drug data, eyes Phase 3 results in 2026 - Investing.com Australia
Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout - The Manila Times
Alumis presents new psoriasis drug data, eyes Phase 3 results in 2026 By Investing.com - Investing.com South Africa
Can Alumis's Fast-Tracked Psoriasis Drug Challenge Market Leaders? Phase 3 Timeline Speeds Up - StockTitan
Alumis to present new data on multiple sclerosis therapy By Investing.com - Investing.com South Africa
Alumis to present new data on multiple sclerosis therapy - Investing.com
Alumis Presents Additional Phase 1 Data at ACTRIMS Forum 2025 Supporting Potential of A-005 as First-in-Class CNS Penetrant TYK2 Inhibitor for Treatment of Neuroinflammatory and Neurodegenerative Diseases - The Manila Times
Can Alumis' Brain-Penetrating Drug Transform Multiple Sclerosis Treatment? Phase 1 Results Suggest Yes - StockTitan
Counteroffer from Tang-backed Concentra could scuttle Acelyrin-Alumis: Deals Report - BioCentury
When (ALMS) Moves Investors should Listen - Stock Traders Daily
Alumis Inc. introduces severance and change in control plan By Investing.com - Investing.com Canada
Alumis Inc. Approves New Severance and Control Plan - TipRanks
Activist investor threatens drug maker's merger plans with L.A. biotech - The Business Journals
Alumis Inc. introduces severance and change in control plan - Investing.com India
Activist investor threatens Peninsula drug maker's merger plansSan Francisco Business Times - The Business Journals
ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences - The Manila Times
Alumis (ALMS) to Release Earnings on Wednesday - MarketBeat
Acelyrin, Inc. Confirms Unsolicited Acquisition Proposal from Concentra Biosciences Amidst Ongoing Merger Agreement with Alumis Inc. - Nasdaq
Can This New Cash Offer Derail ACELYRIN's Planned Alumis Merger? - StockTitan
Alumis Inc Stock (ALMS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.39%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):